|Bid||330.70 x 0|
|Ask||331.00 x 0|
|Day's range||330.50 - 364.10|
|52-week range||115.20 - 411.00|
|Beta (5Y monthly)||1.22|
|PE ratio (TTM)||N/A|
|Earnings date||03 Mar 2022 - 07 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||387.63|
A vaccine maker, a therapeutics company, and a medical lab could suit a variety of investor risk profiles.
Larger order for 2023 follows initial order for supply in 2022 COPENHAGEN, Denmark, August 3, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered a new contract with an undisclosed APAC country for the supply of 350,000 doses of its non-replicating JYNNEOS® smallpox/monkeypox vaccine. Deliveries and all revenues under this contract will occur in 2023 and thus the order has no impact on the financial guidance for this year. Bavarian Nordic signed its first supply contract w
Does Bavarian Nordic (BVNRY) have what it takes to be a top stock pick for momentum investors? Let's find out.